Medincell (MDCLF) Q2 2021 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Medincell Sa.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.049 -- 00:00:05.012 Hello, everyone. Welcome to this video conference dedicated to the presentation of our 00:00:05.012 -- 00:00:10.765 half-yearly results, meaning the period from April 1 to September 30, 2021. 00:00:12.137 -- 00:00:16.019 Today, we published two documents after the close of the stock market. 00:00:16.019 -- 00:00:20.943 Firstly, a press release with a summary of our financials for this period. 00:00:20.943 -- 00:00:25.646 Secondly, an extended report that you can download on our website. 00:00:25.646 -- 00:00:29.935 This conference will last 45 minutes maximum. 00:00:29.935 -- 00:00:34.739 You can send your question by using the chat module to the right of your screen. 00:00:34.739 -- 00:00:37.079 You can also 00:00:37.621 -- 00:00:42.144 like the questions so that they are given higher priority. 00:00:42.144 -- 00:00:46.808 For this meeting, I'm in Paris with Christophe Douac, CEO of Making Cell. 00:00:46.808 -- 00:00:50.751 Hello, Christophe. Hello, David. Hi to all. 00:00:50.751 -- 00:00:54.054 And Remy Arambo, our chief financial officer. 00:00:54.054 -- 00:00:57.511 Hello, Remy. Hello, David. Hello, everyone. 00:00:57.511 -- 00:01:03.133 Joël Richard, our Chief Development Officer, is joining us live from our headquarters 00:01:03.133 -- 00:01:06.234 in Montpellier. Hello, Richard. Hello, Loël, sorry. 00:01:06.234 -- 00:01:08.335 Hello, everybody. 00:01:08.335 -- 00:01:13.717 So, we will start with an update of our portfolio of products based on our long-acting 00:01:13.717 -- 00:01:18.779 injectable technology, BIPO. The main event is obviously the progress 00:01:18.779 -- 00:01:22.399 of our most advanced product, NDC-IRM, 00:01:22.840 -- 00:01:28.588 a program developed with TIVA we have two major announcements in the past m...